Abstract
To date, there are no FDA-approved treatments for Female Sexual Arousal Disorder (FSAD), a sexual dysfunction characterized by diminished vaginal lubrication, decreased clitoral and labial sensation and reduced genital engorgement. As research supports the role of the NO-cGMP smooth muscle-mediated vasodilatory pathway in the female genital arousal response, Sildenafil Cream, 3.6%, a novel topical formulation in Phase 2 clinical development, could become a first-in-class therapy for FSAD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
